-0.41%
10.50%
23.66%
16.33%
17.49%
24.63%
82.54%
AI Spotlight on ALKS
Company Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally.Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases.The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells.
It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International.Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Market Data
| Last Price | 31.78 |
| Change Percentage | -0.41% |
| Open | 31.69 |
| Previous Close | 31.91 |
| Market Cap ( Millions) | 5142 |
| Volume | 569356 |
| Year High | 32.88 |
| Year Low | 22.9 |
| M A 50 | 29.61 |
| M A 200 | 26.95 |
Financial Ratios
| FCF Yield | 6.12% |
| Dividend Yield | 0.00% |
| ROE | 26.49% |
| Debt / Equity | 28.33% |
| Net Debt / EBIDTA | -8.31% |
| Price To Book | 4.02 |
| Price Earnings Ratio | 15.6 |
| Price To FCF | 16.34 |
| Price To sales | 3.42 |
| EV / EBITDA | 14.05 |
News
- Jan -02 - Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Nov -25 - Alkermes to Participate in Upcoming Investor Conferences
- Nov -24 - Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth
- Nov -11 - Alkermes to Participate in Two Upcoming Investor Conferences
- Nov -07 - Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences
- Oct -25 - Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down
- Oct -24 - Alkermes plc (ALKS) Q3 2024 Earnings Call Transcript
- Oct -24 - Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
- Oct -24 - Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates
- Oct -24 - Alkermes plc Reports Third Quarter 2024 Financial Results
- Oct -22 - Alkermes (ALKS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
- Oct -17 - Alkermes to Report Third Quarter Financial Results on October 24, 2024
- Sep -25 - Alkermes to Host Investor Event to Review Orexin Portfolio Strategy
- Sep -23 - Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024
- Sep -13 - Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program
- Aug -28 - Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
- Aug -23 - Alkermes (ALKS) Begins Narcolepsy Type 2 Study on ALKS 2680
- Aug -22 - Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2
- Jul -25 - Alkermes' (ALKS) Q2 Earnings Miss Estimates, Revenues Beat
- Jul -24 - Alkermes (ALKS) Reports Q2 Earnings: What Key Metrics Have to Say
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Product
Expected Growth : 8.97 %
What the company do ?
Alkermes plc's product portfolio includes medications for addiction, schizophrenia, and depression, such as Vivitrol and Aristada, among others.
Why we expect these perspectives ?
Alkermes plc's 8.97% growth is driven by increasing demand for its mental health and addiction treatment products, such as Vivitrol and Aristada. Strong sales growth in the US market, coupled with expanding pipeline and strategic partnerships, contribute to the company's growth momentum.
Segment n°2 -> Manufacturing and Royalty
Expected Growth : 8.9 %
What the company do ?
Alkermes plc's Manufacturing segment produces and sells its proprietary products, while the Royalty segment earns revenue from licensing its intellectual property to other companies.
Why we expect these perspectives ?
Alkermes plc's 8.9% growth in Manufacturing and Royalty segments is driven by increasing demand for its proprietary products, such as Vivitrol and Aristada, as well as growing royalties from its partnerships, particularly with Indivior. Additionally, the company's strategic investments in R&D and manufacturing capacity expansions have improved operational efficiency, contributing to the segment's growth.
Segment n°3 -> Research and Development
Expected Growth : 8.5 %
What the company do ?
Alkermes plc's Research and Development focuses on innovative treatments for central nervous system disorders, addiction, and oncology, driving advancements in medicine.
Why we expect these perspectives ?
Alkermes plc's 8.5% R&D growth driven by increasing investment in pipeline expansion, particularly in CNS and oncology therapeutic areas. Strong demand for innovative treatments and growing partnerships with pharmaceutical companies also contribute to growth. Additionally, the company's focus on digital health and technology advancements supports R&D expansion.
Alkermes Plc Products
| Product Range | What is it ? |
|---|---|
| Vivitrol | A medication-assisted treatment for opioid and alcohol dependence |
| Aristada | An atypical antipsychotic medication for the treatment of schizophrenia |
| Vivitrol Co-pay Savings Program | A patient assistance program for Vivitrol |
| Risperdal Consta | An atypical antipsychotic medication for the treatment of schizophrenia and bipolar I disorder |
| Invega Sustenna | An atypical antipsychotic medication for the treatment of schizophrenia |
| Xeplion | An atypical antipsychotic medication for the treatment of schizophrenia |
Alkermes plc's Porter Forces
Threat Of Substitutes
Alkermes plc operates in a highly regulated industry, which limits the threat of substitutes. However, the company's dependence on a few key products makes it vulnerable to competition from alternative treatments.
Bargaining Power Of Customers
Alkermes plc's customers, primarily healthcare providers and patients, have limited bargaining power due to the company's strong brand recognition and limited competition in certain therapeutic areas.
Bargaining Power Of Suppliers
Alkermes plc relies on a few key suppliers for raw materials and manufacturing services, which gives them some bargaining power. However, the company's scale and diversification efforts mitigate this risk.
Threat Of New Entrants
The pharmaceutical industry has high barriers to entry, including significant regulatory hurdles and capital requirements, which limits the threat of new entrants.
Intensity Of Rivalry
Alkermes plc operates in a highly competitive industry, with several established players and a high level of marketing and R&D expenditure. This intensity of rivalry puts pressure on the company's pricing and market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 19.47% |
| Debt Cost | 6.43% |
| Equity Weight | 80.53% |
| Equity Cost | 6.83% |
| WACC | 6.75% |
| Leverage | 24.17% |
Alkermes plc : Quality Control
Alkermes plc passed 9 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| JAZZ | Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of … |
| CAMX.ST | Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine … |
| ZEAL.CO | Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, … |
| ALK-B.CO | ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis … |
| GMAB.CO | Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
ALK-Abelló
A-Score
1-Year Total Return ->
🥈
Genmab
A-Score
1-Year Total Return ->
🥉
Jazz Pharmaceuticals
A-Score
1-Year Total Return ->
4
Camurus
A-Score
1-Year Total Return ->
5
Alkermes
A-Score
1-Year Total Return ->
6
